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1 Research questions 
The HTA Core Model
®
 for Rapid Relative Effectiveness Assessment of 
Pharmaceuticals was used for structuring this report [1]. The Model organ-
ises HTA information according to predefined generic research questions. 
Based on these generic questions, the following research questions were an-
swered in the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is venetoclax? 
A0022 Who manufactures venetoclax? 
A0007 What is the target population in this assessment? 
A0020 For which indications has venetoclax received marketing authorisation? 
Health problem and current use 
A0002 What is CLL? 
A0004 What is the natural course of CLL? 
A0006 What are the consequences of CLL for the society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of CLL? 
A0003 What are the known risk factors for CLL? 
A0024 How is CLL currently diagnosed according to published guidelines and in practice? 
A0025 How is CLL currently managed according to published guidelines and in practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of venetoclax on mortality? 
D0006 How does venetoclax affect progression (or recurrence) of CLL? 
D0005 How does venetoclax affect symptoms and findings (severity, frequency) of CLL? 
D0011 What is the effect of venetoclax on patients’ body functions? 
D0012 What is the effect of venetoclax on generic health-related quality of life? 
D0013 What is the effect of venetoclax on disease-specific quality of life? 
Safety 
C0008 How safe is venetoclax in relation to no intervention? 
C0002 Are the harms related to dosage or frequency of applying venetoclax? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through the 
use of venetoclax? 
A0021 What is the reimbursement status of venetoclax? 
 
 
 
 
EUnetHTA 
HTA Core Model® 
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2 Drug description 
Generic/Brand name/ATC code:  
Venetoclax/Venclexta
TM
/L01XX52 
 
B0001: What is venetoclax? 
Venetoclax is an oral, selective, small-molecule inhibitor of the pro-survival 
B-cell lymphoma 2 (BCL-2) proteins [2-4]. Overexpression of BCL-2 can 
cause increased apoptosis resistance and prolonged survival of chronic lym-
phocytic leukaemia (CLL) B-cells [5]. Venetoclax binds the BCL-2 protein 
directly, displaces pro-apoptotic proteins like BIM (BCL-2-like protein 11), 
triggers mitochondrial outer membrane permeabilisation and activates 
caspases. These processes help to restore the apoptotic ability of malignant 
cells [3, 4].  
The recommended daily dose of venetoclax is 400 mg until disease progres-
sion or unacceptable toxicity is observed. The initial daily dose starts at 20 
mg for 7 days, followed by a weekly ramp-up dosing schedule over 5 weeks 
until 400 mg have been reached. This should gradually reduce tumour bur-
den as well as decrease the risk of tumour lysis syndrome. Venetoclax tablets 
should be administered daily with a meal and water at about the same time 
[3].  
 
A0022: Who manufactures venetoclax? 
AbbVie Inc. & Genentech USA, Inc. 
 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Venetoclax (Venclexta
TM
) is indicated for the treatment of relapsed or re-
fractory CLL patients with chromosome 17p deletion (del[17p]), who have 
received at least one prior therapy. 
 
 
 
 
BCL-2 specific, small-
molecule inhibitor 
once daily 400 mg after 
a weekly dose ramp-up 
schedule 
indicated for 
relapsed/refractory 
del(17p) CLL 
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4 Current regulatory status 
A0020: For which indications has venetoclax received marketing authorisa-
tion? 
In April 2016, the US Food and Drug Administration (FDA) approved ve-
netoclax for the treatment of CLL patients with del(17p), as determined by 
an FDA-approved test (Vysis CLL FISH probe kit, Abbott-Molecular, Des 
Plaines, IL, USA), and who have received at least one prior therapy. Veneto-
clax has been approved under accelerated approval and received orphan sta-
tus based on the interim analysis of a single-arm phase II study (M13-982) 
[3].  
Venetoclax has not yet been approved by the European Medicines Agency 
(EMA), but it received orphan designation in February 2016 for the treat-
ment of acute myeloid leukaemia patients who are older than 65 years and 
who cannot receive standard treatment. Confirmation of a significant benefit 
for this patient group is needed at the time of marketing authorisation to re-
tain the orphan status [6]. 
 
 
 
5 Burden of disease 
A0002: What is CLL? 
CLL is a B-cell chronic lymphoproliferative disorder (lymphoid neoplasm) 
that pertains to the B-cell non-Hodgkin lymphomas (NHL) [7]. It is charac-
terised by the clonal proliferation as well as the accumulation of mature, 
functionally incompetent and typically CD5-positive B-cells within the 
blood, bone marrow, lymph nodes and spleen [7-9]. 
 
A0004: What is the natural course of CLL? 
Typically, CLL is characterised by a highly variable course of disease, 
whereby the majority of patients will have an indolent (slow-growing) dis-
ease [7, 9, 10]. Other patients die rapidly (2–3 years) after diagnosis due to 
complications or causes directly related to CLL, whereas others live for 5 to 
10 years with an initial course of disease followed by a terminal course for 1–
2 years. The major causes of death are systematic infections (e.g. pneumonia 
and septicaemia), bleeding and inanition with cachexia [7]. 
 
A0006: What are the consequences of CLL for the society? 
A0023: How many people belong to the target population? 
CLL is the most frequent type of leukaemia in western countries [9, 11]. In 
Austria, the incidence of NHL is 9.0 per 100,000 persons per year (2012); in 
2012, more than 1,200 persons were newly diagnosed. About 60% of all new-
ly diagnosed NHLs were B-cell lymphomas [12]. CLL is most commonly di-
FDA approval for CLL 
since 2016 
venetoclax received 
orphan designation by 
the EMA 
lymphoid neoplasm  
highly variable courses 
of disease 
NHL incidence rate in 
Austria 9.0 per 100,000 
persons/year 
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agnosed among people aged between 65 and 74 years; the median age 
at diagnosis is about 71 years [13]. 5–10% of CLL patients have a detectable 
del(17p) or a mutation of the p53 gene [14]. In Austria, men have 1.4 times 
higher incidence and 1.8 times higher mortality rates than women [12]. 
 
A0005: What are the symptoms and the burden of CLL? 
Typically, CLL patients do not show any signs or symptoms. However, if 
symptoms or signs are present they can occur in a wide range, like painless 
swelling of the lymph nodes (e.g. cervical area, neck and stomach), pain be-
low the ribs, tiredness, lymphadenopathy, splenomegaly and hepatomegaly 
[11, 15]. Nevertheless, only 5–10% of CLL patients show one or more of the 
so called “B symptoms”, which include unintentional weight loss, fevers and 
night sweats without evidence of infection, and extreme fatigue [11]. 
 
A0003: What are the known risk factors for CLL? 
Predisposition to CLL due to occupational or environmental risks is not de-
finitively discernible [11]. Risk factors associated with CLL are a family his-
tory of CLL or other lymph-related cancers, older age, gender (men are more 
often affected than women) and ethnicity [9, 16]. 
 
A0024: How is CLL currently diagnosed according to published guidelines 
and in practice? 
The diagnosis of CLL is established via blood counts, blood smears, and 
immunophenotyping of circulating B-lymphocytes (≥ 5 x 109/L) [9, 17]. 
However, often CLL is diagnosed during routine blood count tests that re-
veal an absolute lymphocytosis [11]. An additional computed tomography 
(CT) may be performed in patients suspected of having enlarged abdominal 
or pelvic nodes [7]. 
CLL patients are prognostically grouped following the Rai and the Binet 
staging systems, based on physical examination and complete blood counts 
[7, 9, 10]. The Rai staging system is based on the idea that CLL is a gradual 
and progressive increase in the body burden of leukaemic lymphocytes start-
ing from lymphocytosis. It consists of the following three groups [7]: 
 Stage 0 (low risk): lymphocytosis 
 Stages I to II (intermediate risk): lymphadenopathy, organomegaly 
 Stages III to IV (high risk): anaemia, thrombocytopenia. 
In contrast, the Binet staging system takes five potential areas of involve-
ment into consideration: cervical, axillary, inguinal lymph nodes, spleen and 
liver. The classification of patients is based on the number of involved sites 
as well as the presence of anaemia and/or thrombocytopenia [7, 9]: 
 Stage A: fewer than three involved lymphoid sites  
 Stage B: at least three involved lymphoid sites  
 Stage C: existence of anaemia and/or thrombocytopenia. 
Additionally, lymphocyte doubling time, beta-2 microglobulin, and genetic 
abnormalities can be further prognostic factors [7]. 
median age at diagnosis: 
71 
usually CLL does not 
cause any signs or 
symptoms 
associated risk factors: 
gender, ethnicity, age 
and family history 
often diagnosed via 
routine blood count 
tests 
two staging systems: 
Binet and Rai 
Binet staging system is 
based on the number of 
involved sites 
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6 Current treatment 
A0025: How is CLL currently managed according to published guidelines 
and in practice? 
Immediate treatment is indicated in CLL patients that show an active dis-
ease which is manifested by advanced stage, high tumour burden, severe 
disease-related “B symptoms” or repeated infections. Otherwise, the majori-
ty of early-stage CLL patients are managed initially with watchful waiting. 
In general, patient fitness, comorbidities as well as the patient’s performance 
status should be determined prior to the initiation of treatment [17, 18]. 
Currently, the only curative treatment option for CLL patients is allogeneic 
hematopoietic cell transplantation [18].  
Due to differences in patient age and fitness, no uniform front-line regimen 
is recommended for all symptomatic CLL patients. However, there are sev-
eral initial treatment options available, like chlorambucil-based chemother-
apy, fludarabine, rituximab and cyclophosphamide (FCR) or bendamustine 
plus rituximab [10, 17, 18].  
No standard treatment has yet been established for the treatment of relapsed 
or refractory CLL patients [10]. However, once a patient is considered to 
have relapsed or refractory CLL, the diagnosis has to be reconfirmed by a 
complete blood count with differential flow cytometry of the peripheral 
blood. In addition, FISH testing should be repeated to determine specific 
chromosomal deletions. CLL patients with asymptomatic recurrent CLL do 
not inevitably need instant treatment but should be closely observed [18].  
Generally, treatment options are dependent on the quality and duration of 
response to the previous treatment. Therefore, CLL patients who showed an 
initial response duration that was significantly less than the median for a re-
spective treatment can be considered for another regimen at relapse. For pa-
tients with an early relapse (< 6 months) and those with 17p deletion ibru-
tinib monotherapy could offer a treatment option. If ibrutinib is not tolerat-
ed or contraindications exist, idelalisib plus rituximab may be considered. 
For patients who progress one year after initial therapy (late relapse), re-
treatment with the prior therapy can be an option as well as ibrutinib mono-
therapy or idelalisib plus rituximab [9, 17, 19].  
 
 
 
7 Evidence 
A literature search was conducted on 4 August 2016 in five databases: the 
Cochrane Library, CRD Database, Embase, Ovid Medline and PubMed. 
Search terms were “Venetoclax”, “Venclexta”, “GDC-0199”, “ABT-199”, 
“RG7601”, “chronic lymphocytic leukaemia”, “chronic lymphocytic leu-
kemia” and “CLL”. Also, the manufacturer was contacted, who submitted 
eight references (three of which had already been identified by systematic 
literature search). Manual search identified 25 additional references (web 
documents and journal articles). 
observation in 
asymptomatic CLL 
patients 
1st-line therapy options: 
chlorambucil-based 
chemotherapy, FCR, 
bendamustine + 
rituximab 
no agreed standard 
therapy for relapsed or 
refractory CLL patients 
early relapse and 
del(17p) CLL: clinical 
trials, ibrutinib, idelalisib 
+ rituximab 
 
late relapse CLL: 
retreatment with the 
prior therapy, ibrutinib, 
alternatively idelalisib + 
rituximab 
literature search in 5 
databases: 246 hits 
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Overall, 270 references were identified. Included in this report are: 
 1 phase II study, assessing venetoclax in relapsed or refractory CLL 
patients harbouring a 17p deletion [20, 21] 
 1 phase I study, assessing venetoclax in patients with relapsed or re-
fractory CLL or small lymphocytic lymphoma [22]. 
The methodological quality of the evidence was assessed using a Downs 
and Black instrument [23] that was modified to include the source of fund-
ing for studies. Evidence was assessed based on the reporting of trial char-
acteristics, external and internal validity, and confounding. The form used 
to assess the study quality is reported in Table 4 (see appendix). Study 
strengths and limitations were reported in preference to a numeric score 
and can be found in Table 3 (see appendix).  
 
 
7.1 Clinical efficacy and safety – phase II study 
M13-982 [20, 21] was an open-label, multicentre, single-arm phase II study 
assessing the activity and safety of venetoclax monotherapy in patients with 
relapsed or refractory CLL harbouring a 17p deletion. Reported are the re-
sults of a pre-specified interim analysis; 70 (65%) of 107 patients were on 
treatment at the time of data cut-off (April 2015) and 37 (35%) had discon-
tinued treatment (22 progressed, 9 had adverse events, 2 withdrew consent, 1 
was non-compliant and 3 proceeded to allogenic stem cell transplantation). 
A total of 107 patients were enrolled to receive a 400 mg daily dose of ve-
netoclax until disease progression, unacceptable toxic effects or discontinua-
tion for any other reason. A weekly dose ramp-up from a 20 mg starting dos-
age to the final 400 mg (20, 50, 100, 200, 400 mg) over 4–5 weeks was per-
formed. 
The median duration of follow-up at the time of data cut-off was 12.1 
months, ranging from 10.1 to 14.2 months. The median time from diagnosis 
of CLL to the first venetoclax dose was 81.7 months (interquartile range 
[IQR] 41.0–131.5), and from the last prior therapy to the first dose of veneto-
clax it was 5.4 months (IQR 2.4–16.5). All patients except for one had a 
del(17p), assessed by a central laboratory with the Vysis fluorescence in-situ 
hybridisation (FISH) kit. The median proportion of del(17p) cells was 
50.3%, ranging from 23.0% to 83.5%. 
Enrolled patients were at least 18 years or older and had a median age of 67 
(ranging from 37 to 85) years. Relapsed/refractory CLL was defined as re-
lapsed or refractory after receiving at least one prior line of therapy (patients 
had to receive at least two cycles of the respective treatment). The study 
population had an Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of 2 or less. Detailed patient characteristics including inclu-
sion and exclusion criteria can be found in Table 3. 
The primary outcome of M13-982 was activity of venetoclax monotherapy, 
measured by the proportion of patients who achieved an overall response 
(defined as partial remission and higher) assessed by an independent review 
committee (IRC). The analysis of the primary endpoint was pre-planned to 
be done once 70 patients completed a week 36 assessment. All other analyses 
quality of evidence 
assessed using a 
modified Downs and 
Black instrument 
M13-982: open-label, 
single-arm phase II 
study 
107 relapsed/refractory 
CLL patients 
 
daily dose of 400 mg 
median follow-up 
duration: 12.1 months 
median age of 67 years 
and ECOG performance 
status of 0–2 
primary outcome: 
proportion of patients 
who achieved an overall 
response 
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included all 107 patients who received at least one dose of venetoclax (per-
protocol population). Secondary outcomes comprised the proportion of pa-
tients with complete remission (CR) and partial remission (PR), time to first 
response (TTR), duration of overall response (DOR), progression-free sur-
vival (PFS), overall survival (OS) as well as adverse events (AEs). 
 
7.1.1 Clinical efficacy 
D0001: What is the expected beneficial effect of venetoclax on mortality? 
At the time of interim analysis the median OS (17 deaths) had not been 
reached. The estimated 12-month OS was 86.7% (95% CI 78.6–91.9), as-
sessed by an independent review committee. 
 
D0006: How does venetoclax affect progression (or recurrence) of CLL? 
Median PFS (31 events) had not been reached at the time of interim analy-
sis. The estimated 12-month PFS was 72.0% (95% CI 61.8–79.8) per inde-
pendent review committee assessment. The median time to progression for 
CLL was 6.3 months (IQR 4.4–9.8). The estimated 12 months’ time to pro-
gression (TTP) was 77% (95% CI 67–84). 
 
D0005: How does venetoclax affect symptoms and findings (severity, fre-
quency) of CLL? 
54 (77%) of patients of the pre-specified study population (70 subjects) 
achieved an overall response (OR). An OR assessed by IRC (OR-IRC), in the 
per-protocol population (107 subjects), was achieved in 85 (79.4%, CI 70.5–
86.6) patients. 79 (74%) patients in the per-protocol population assessed by 
the investigator (IA) achieved an OR. CR or CR with incomplete blood re-
covery of blood counts was achieved in 8 (8%) patients assessed by IRC. A 
PR in the per-protocol population was achieved in 74 (69%, ICR assessed) 
patients and a nodular partial remission (NPR) in 3 (3%) patients. 
 
D0011: What is the effect of venetoclax on patients’ body functions? 
No evidence was found to answer this research question. 
D0012: What is the effect of venetoclax on generic health-related quality of 
life? 
No evidence was found to answer this research question. 
 
D0013: What is the effect of venetoclax on disease-specific quality of life? 
There was no evidence found to answer this research question but patient-
reported outcome measures will be investigated in a safety expansion cohort 
of the M13-982 trial.  
 
median OS had not been 
reached, estimated 12-
month OS: 86.7% 
median PFS had not 
been reached, estimated 
12-month PFS: 72.0% 
OR-IRC: 79% 
CR-IRC: 7%  
PR-IRC: 69% 
NPR-IRC: 3% 
QoL data will be 
investigated in a safety 
expansion cohort 
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Table 1: Efficacy results of trial M13-982 
Descriptive statistics 
and estimate varia-
bility 
Treatment group Venetoclax 
Number of subjects 107 
OR 
OR-IRC (n = 70)1, n (%) 54 (77) 
OR-IRC, n (%) 
95% CI 
85 (79) 
70.5–86.6 
CR-IRC2, n (%) 8 (8) 
PR-IRC, n (%) 74 (69) 
NPR-IRC, n (%) 3 (3) 
OR-IA, n (%) 79 (74) 
PFS Median PFS, months 
12-month PFS, % 
95% CI 
NR 
72.0 
61.8–79.8 
OS Median OS, months 
12-month OS, % 
95% CI 
NR 
86.7 
78.6–91.9 
Abbreviations: CI = confidence interval, CR = complete remission, IA = assessed by an investigator, ICR 
= assessed by an independent review committee, NPR = nodular partial remission, NR = not reached, 
OR = overall response, OS = overall survival, PFS = progression-free survival, PR = partial remission 
 
7.1.2 Safety 
C0008: How safe is venetoclax in relation to no intervention? 
As the M13-982 trial was a single-arm study, no results comparing veneto-
clax to a comparator are available. However, the treatment-related grade 3–4 
AEs that occurred most commonly in the per-protocol population were neu-
tropenia (40%), infection (20%), anaemia (18%) and thrombocytopenia 
(15%). Serious infections that occurred in at least two patients were pneu-
monia (6%), lower respiratory tract infection (2%) and upper respiratory 
tract infection (2%). Grade 5 AEs occurred in 12 (11%) patients, of which 
seven had a malignant neoplasm progression. In total, 18 (17%) patients 
died in the course of the study, of which seven died due to disease progres-
sion, four because of an AE and seven due to progressive disease after 30 
days from discontinuation of venetoclax. All treatment-emergent AEs can be 
found in Table 2.  
 
C0002: Are the harms related to dosage or frequency of applying venetoclax? 
                                                             
1
 Pre-planned analysis of overall response that was performed once 70 patients com-
pleted a week 36 assessment 
2
 Complete remission or complete remission with incomplete recovery of blood 
counts 
most common grade 3–4 
AEs: neutropenia, 
infection, anaemia, and 
thrombocytopenia 
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In a total of 13 (12%) patients (107 subjects), dose reductions were required 
owing to AEs. Dose interruptions or reductions, or granulocyte-colony stim-
ulating factor treatment and antibiotics were necessary due to grade 3–4 AE 
neutropenia. Infections led to an interruption of treatment with venetoclax 
in 10 (9%) patients and to dose reductions in two (2%) patients. In two (2%) 
patients, treatment interruptions were also indicated in consequence of tu-
mour lysis syndrome. 
 
C0005: What are the susceptible patient groups that are more likely to be 
harmed through the use of venetoclax? 
In previously treated CLL patients with high tumour burden, hyperuricae-
mia or chronic kidney disease, the treatment with venetoclax can cause tu-
mour lysis syndrome, including fatal events and renal failure requiring dial-
ysis. Furthermore, venetoclax may cause embryofoetal harm when adminis-
tered to a pregnant woman. However, there are no adequate and well-
controlled studies available investigating venetoclax in pregnant women [3]. 
 
Table 2: Most frequent treatment-related adverse events
3
 
Adverse event (according  
to NCI-CTC version 4.0) Venetoclax (n = 107) 
 Grade 1–2 
n (%) 
Grade 3 
n (%) 
Grade 4 
n (%) 
Grade 5 
n (%) 
Any treatment-related AEs 22 (21) 37 (35) 32 (30) 12 (11) 
Blood and lymphatic disorders 8 (8) 26 (24) 31 (29) 0 (0) 
Anaemia 10 (9) 19 (18) 0 (0) 0 (0) 
Autoimmune haemolytic 
anaemia 
1 (1) 4 (4) 3 (3) 0 (0) 
Febrile neutropenia 0 (0) 4 (4) 1 (1) 0 (0) 
Immune thrombocytopenia 
purpura 
0 (0) 1 (1) 4 (4) 0 (0) 
Leukopenia 0 (0) 4 (4) 1 (1) 0 (0) 
Neutropenia 3 (3) 18 (17) 25 (23) 0 (0) 
Thrombocytopenia 4 (4) 4 (4) 12 (11) 0 (0) 
Cardiac disorders 7 (7) 4 (4) 0 (0) 1 (1) 
Atrial fibrillation 4 (4) 2 (2) 0 (0) 0 (0) 
Cardiopulmonary failure 0 (0) 0 (0) 0 (0) 1 (1) 
Gastrointestinal disorders 60 (56) 7 (7) 0 (0) 0 (0) 
Constipation 11 (10) 0 (0) 0 (0) 0 (0) 
Diarrhoea 31 (29) 0 (0) 0 (0) 0 (0) 
Nausea 30 (28) 1 (1) 0 (0) 0 (0) 
Vomiting 15 (14) 1 (1) 0 (0) 0 (0) 
General disorders 54 (51) 4 (4) 1 (1) 1 (1) 
Disease progression 0 (0) 0 (0) 0 (0) 1 (1) 
Fatigue 23 (22) 0 (0) 0 (0) 0 (0) 
 
                                                             
3
 Reported are grade 1–2 AEs occurring in at least 10% of patients, grade 3–4 AEs in 
two or more patients and all grade 5 AEs 
dose reductions due to 
AEs (neutropenia, 
infection, etc.) 
tumour lysis syndrome 
and embryo-foetal harm 
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Pyrexia 20 (19) 1 (1) 0 (0) 0 (0) 
Hepatobiliary disorders 2 (2) 2 (2) 0 (0) 1 (1) 
Hepatic function abnormal 0 (0) 0 (0) 0 (0) 1 (1) 
Hyperbilirubinaemia 0 (0) 2 (2) 0 (0) 0 (0) 
Infections and infestations 56 (52) 14 (13) 6 (6) 1 (1) 
Lower respiratory tract 
infection 
4 (4) 2 (2) 0 (0) 0 (0) 
Nasopharyngitis 15 (14) 0 (0) 0 (0) 0 (0) 
Pneumocystis jirovecii 
pneumonia 
0 (0) 2 (2) 0 (0) 0 (0) 
Pneumonia 4 (4) 4 (4) 1 (1) 0 (0) 
Septic shock 0 (0) 0 (0) 0 (0) 1 (1) 
Upper respiratory tract 
infection 
14 (13) 0 (0) 2 (2) 0 (0) 
Neoplasms benign, malignant, 
and unspecified 
5 (5) 9 (8) 3 (3) 7 (7) 
Malignant neoplasm 
progression 
1 (1) 2 (2) 1 (1) 7 (7) 
Squamous cell carcinoma of 
skin 
2 (2) 2 (2) 0 (0) 0 (0) 
Nervous system disorders 28 (26) 3 (3) 2 (2) 1 (1) 
Headache 12 (11) 0 (0) 0 (0) 0 (0) 
Haemorrhagic stroke 0 (0) 0 (0) 0 (0) 1 (1) 
Vascular disorders 9 (8) 7 (7) 0 (0) 0 (0) 
Hypertension 2 (2) 4 (4) 0 (0) 0 (0) 
Abbreviations: AEs = adverse events, NCI-CTC = National Cancer Institute Common Terminology Criteria for Adverse 
Events 
 
7.2 Clinical efficacy and safety – further studies 
A multicentre, non-randomised, open-label, phase I dose-escalation study 
[22] was conducted to assess the safety, pharmacokinetic profile, and effica-
cy of venetoclax in patients with relapsed or refractory CLL or small lym-
phocytic lymphoma (SLL). 56 patients were included in a dose-escalation 
phase: they received active treatment in one of eight dose groups that ranged 
from 150 to 1,200 mg per day. 60 additional patients were enrolled in an ex-
pansion cohort to receive weekly gradual ramp-up in doses as high as 
400 mg per day.  
In 3 of 56 patients of the dose-escalation cohort, tumour lysis syndrome oc-
curred, leading to one death. After that, doses were adjusted, and no tumour 
lysis syndrome occurred in any of the 60 patients in the expansion cohort. 
Further toxic effects included mild diarrhoea (52%), upper respiratory tract 
infection (48%), nausea (47%), and grade 3–4 neutropenia (41%). No maxi-
mum tolerated dose could be identified. 92 (79%) of 116 patients showed a 
response to venetoclax. A CR was achieved in 20% of patients. A 15-month 
progression-free survival estimate of 69% was found for 400 mg venetoclax. 
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8 Estimated costs 
A0021: What is the reimbursement status of venetoclax? 
To date, venetoclax is not approved in Europe; therefore, there are no price 
estimates available for Austria at this point. However, additional costs will 
incur due to tumour lysis syndrome prophylaxis. 
 
 
 
9 Ongoing research 
In August 2016, a search in databases www.clinicaltrials.gov and 
www.clinicaltrialsregister.eu was conducted. The following 3 ongoing phase 
III trials are investigating venetoclax in patients with CLL: 
 NCT02756611: An open-label, single-arm, phase IIIb multicentre 
study evaluating the efficacy of venetoclax (ABT-199) in re-
lapsed/refractory subjects with chronic lymphocytic leukaemia 
(CLL) including those with the 17p deletion or TP53 mutation or 
those who have received prior treatment with a B-cell receptor in-
hibitor. Estimated study completion date is August 2020. 
 NCT02005471: A multicentre, phase III, open-label randomised 
study in relapsed/refractory patients with chronic lymphocytic leu-
kaemia to evaluate the benefit of GDC-0199 (ABT-199) plus ritux-
imab compared with bendamustine plus rituximab. Estimated 
study completion date is September 2020. 
 NCT02242942: An open-label, multicentre, randomised phase III 
study is designed to compare the efficacy and safety of a combined 
regimen of obinutuzumab and GDC-0199 versus obinutuzumab + 
chlorambucil (GClb) in patients with chronic lymphocytic leukae-
mia (CLL) and coexisting medical conditions. Estimated study 
completion date is November 2018.  
Various phase I and II studies are currently ongoing in different treatment 
lines and regimens in patients with CLL (e.g. NCT02427451, NCT02756897, 
NCT01328626, NCT01682616, NCT02141282 and NCT01685892). In addi-
tion, venetoclax is also currently investigated for other indications, like mul-
tiple myeloma, acute myelogenous leukaemia, diffuse large B-cell lympho-
ma, small lymphocytic lymphoma, mantle cell lymphoma and follicular 
lymphoma. 
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10 Discussion 
Since April 2016, venetoclax has been approved by the FDA for the treat-
ment of CLL patients with 17p deletion, as determined by an FDA-
approved test (Vysis CLL FISH probe kit), who have received at least one 
prior therapy [3]. In Europe, venetoclax has not yet received marketing au-
thorisation but it received orphan designation for the treatment of acute my-
eloid leukaemia in February 2016 [6]. 
The FDA approval was based on a multicentre, open-label, single-arm phase 
II study, the M13-982 trial [20, 21]. The study was conducted to assess the 
activity and safety of venetoclax monotherapy in 107 patients with relapsed 
or refractory CLL harbouring a 17p deletion. An OR-IRC was achieved in 85 
(79.4%) patients at a median follow-up of 12.1 months. 8% of patients 
showed a CR-IRC. Neither median OS, median PFS nor median DOR had 
not been reached at the time of analysis. In general, the prognosis of patients 
with del(17p) is poor [24, 25]. However, poor-risk cytokinetics like del(17p) 
were also associated with a shorter duration of response in former studies 
[25, 26]. This fact highlights the requirement for mature efficacy data. 
Since 46 (43%) patients were under 65 years and CLL is most commonly di-
agnosed among people aged between 65 and 74, the study population reflect-
ed younger patients than are common in clinical practice. In addition, an ex-
tensive efficacy and safety profile for patients harbouring an IGVH mutation 
is necessary due to the small sample size (7 patients) of this subgroup and to 
exclude any disadvantages, as this patient group achieved a 15% less 12-
month PFS estimate compared to the overall population.  
In regard to safety outcomes, 65% of the per-protocol population experi-
enced treatment-related grade 3–4 AEs (most frequent: neutropenia, infec-
tion, anaemia, and thrombocytopenia), another 11% of patients had grade 5 
AEs and 17% of patients had died in the course of the study. No patient-
reported outcomes, like quality of life (QoL), were available. These measures 
will be examined in a safety expansion cohort of the M13-982 trial. Those re-
sults should be taken into consideration and also set into relation to the final 
efficacy and safety results.  
In former studies, venetoclax has shown an increased risk of tumour lysis 
syndrome via the rapid reduction of tumour cells [22]. Therefore, prophylax-
is and management have been implemented in the M13-982 trial. As a re-
sult, tumour lysis syndrome occurred in only five patients. However, once 
venetoclax is available in Europe, it will be of high importance to introduce 
this prophylaxis into clinical practice and take its additional costs into con-
sideration.  
There is currently no appropriate treatment option defined for CLL patients 
with del(17p), but they are at high risk of either not responding to initial 
treatment with chemo-immunotherapy or relapsing rapidly after achieving 
remission. However, frontline treatment with kinase inhibitors (e.g. ibru-
tinib) is associated with treatment success [24]. In the M13-982 trial, only 5 
patients were previously treated with a kinase inhibitor, of whom four 
achieved a partial remission and one was a non-responder. Further studies 
are needed to verify a clinical benefit for this critical patient group. Howev-
er, there is an ongoing trial investigating the efficacy and safety of veneto-
clax in patients who were previously treated with idelalisib and/or ibrutinib. 
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Due to the single-arm design of the trial, several limitations occur. Inter-
preting the treatment effect is especially difficult. Besides the comparative 
efficacy of the treatment, responses may be influenced by an effect of the 
natural history of the disease. Another limitation due to the lack of a com-
parator is that a positive effect of the treatment could be missed [27]. In ad-
dition, the single-arm design can also lead to various biases besides the 
treatment effect, that can affect clinical outcomes [28]. Venetoclax should 
therefore be compared to other treatment options (e.g. kinase inhibitors). 
This could have the additional advantage of yielding information as to 
which drug the patients benefit from the most and thus enable the estab-
lishment of treatment recommendations based on direct head-to-head com-
parison data. Furthermore, another limiting factor of the study was the 
small sample size. To enhance the chance of detecting a true effect, a higher 
study population would be necessary [29]. Follow-up may have been insuffi-
cient to fully determine intended effects, including DOR, PFS, OS, and all 
potential serious AEs. 
Due to considerable selection pressure for cancer cells to escape elimination, 
the development or selection of resistant clones may be a problem with ve-
netoclax treatment [30]. The mechanism of resistance with venetoclax has 
not yet been described in CLL patients [31]. One mechanism would be the 
up-regulation of alternate anti-apoptotic BCL2 family members (e.g. BCL-
XL, BCL-W, MCL1 and BCL2A1), like ABT-737 (inhibitor of BCL2 and 
BCL-XL), which induces resistance by up-regulating BCL-XL and BCL2A1 
[32, 33]. Combination therapies with kinase inhibitors or anti-CD20 anti-
bodies may be an option to achieve long-term and complete CLL remission 
with venetoclax [30, 31]. Two combination therapies are currently under in-
vestigation in two phase III trials for the treatment of CLL (NCT02005471 
and NCT02242942) [34, 35].  
Overall, as no agreed upon standard care exists as yet for the treatment of re-
lapsed or refractory CLL patients with del(17p), venetoclax might be a 
treatment option for this indication. Nevertheless, although an OR was 
achieved in 79.4% of patients, only 8% of them showed a CR. Furthermore, 
a randomised controlled trial (RCT) will be necessary to compare safety and 
efficacy outcomes in order to reliably interpret the actual treatment effect. 
Furthermore, mature data is needed to evaluate the efficacy and safety of 
venetoclax, including in regard to long-term effects and potential resistance 
mechanisms. There are currently no price estimates available for venetoclax 
for Austria, but costs incurring as a result of tumour lysis syndrome prophy-
laxis must be taken into account as well in this regard, if venetoclax receives 
marketing authorisation in Europe. 
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12 Appendix  
Table 3: Characteristics of trial M13-982 
Title: Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label phase 2 
study [20, 21] 
Study identifier NCT01889186,EudraCT number 2012-004027-20, M13-982 
Design Phase II, single-arm, open-label, multicentre 
Duration Enrolment: May 2013 to June 2014 
 Median follow-up: 12.1 months (range: 10.1–14.2) 
 Data cut-off: 2015-04-30 
Hypothesis Exploratory 
The study was designed to assess the activity of venetoclax in patients with relapsed/refractory CLL 
with del(17p). The analysis for the primary study endpoint was pre-specified to be done once 70 pa-
tients completed a week 36 assessment (90% power at a two sided α of 5%). 
Funding AbbVie Inc. & Genentech USA, Inc. 
Treatment group Intervention (n = 107) Venetoclax with a weekly dose ramp-up schedule (20, 50, 
100, 200, 400 mg) over 4–5 weeks until a continuous daily 
dose of 400 mg had been reached – oral 
Endpoints and definitions Activity of ve-
netoclax mono-
therapy (primary 
endpoint) 
- 
Measured by the proportion of patients who achieved an 
overall response (OR; partial remission or higher) assessed 
by an independent review committee 
Time to first re-
sponse  
TTR Time from first dose to first response 
Progression-free 
survival PFS 
Number of days from the date of first dose to the date of 
earliest disease progression or death 
Overall survival OS Number of days from the date of first dose to the date of death for all dosed patients 
Duration of over-
all response 
DOR Number of days from the date of first response to the ear-
liest recurrence or disease progression per the independent 
review committee assessment 
Results and analysis  
Analysis description 
Primary analysis 
The primary endpoint was assessed once 70 patients completed a week 36 assessment. 
Safety and all other activity analyses were assessed in the per-protocol population. 
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Title: Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label phase 2 
study [20, 21] 
Study identifier NCT01889186,EudraCT number 2012-004027-20, M13-982 
Analysis population  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion 
 Age ≥ 18 years  
 Diagnosed CLL that meets published 2008 Modified IWCLL NCI-WG Guide-
lines 
 Indication for treatment according to the 2008 Modified IWCLL NCI-WG 
Guidelines 
 Measurable disease (lymphocytosis > 5 × 109/L and/or palpable and measura-
ble nodes by physical exam and/or organomegaly assessed by physical exam) 
 Refractory/relapsed disease after receiving at least one prior line of therapy or 
previously untreated CLL  
 del(17p) > 7% of cells in peripheral blood (assessed by local or central labora-
tory) 
 ECOG performance status of 0–2 
 Adequate bone marrow function:  
- ANC ≥ 1000/µL 
- ANC < 1000/µL at screening, and bone marrow heavily infiltrated with un-
derlying disease; growth factor support may be administered after screening 
and prior to the first dose of venetoclax to achieve the ANC eligibility criteria 
- Platelets > 30,000/mm3 
- Haemoglobin ≥ 8.0 g/dL 
 Adequate coagulation, renal, and hepatic function, per laboratory reference 
range at screening: 
- aPTT and PT not to exceed 1.5 × the upper limit of normal 
- Calculated creatinine clearance > 50 mL/min 
- AST and ALT ≥ 3.0; Bilirubin ≥ 1.5  
 For high-risk tumour lysis syndrome patients a pre-approval by the AbbVie 
medical monitor is required prior to enrolment 
 
Exclusion 
 Performed allogeneic stem cell transplant 
 Confirmed Richter’s transformation (by biopsy) 
 Prolymphocytic leukaemia 
 Active and uncontrolled autoimmune cytopenia (for two weeks prior to 
screening), compromising autoimmune haemolytic anaemia and idiopathic 
thrombocytopenic purpura despite low-dose corticosteroids 
 Prior treatment with venetoclax  
 Biologic agent given with anti-neoplastic intent within 30 days prior to the 
first dose of venetoclax 
 Patient had received one of the following within 14 days or five half-lives, as 
applicable, prior to the first dose of the study drug, or has not recovered to less 
than CTC grade 2 clinically significant adverse effect(s)/toxicity(s) of the pre-
vious therapy: 
 - Any anti-cancer therapy including chemotherapy or radiotherapy 
 - Investigational therapy, including targeted small-molecule agents 
 Allergy to both xanthine oxidase inhibitors and rasburicase 
 
Characteristics 
 
Venetoclax 
Median age (range), years 
≥ 65 years, n (%) 
< 65 years, n (%) 
67 (37–85) 
61 (57) 
46 (43) 
Gender, n (%) 
♀ 37 (35) 
♂ 70 (65) 
ECOG performance status, n (%) 
0 
1 
2 
 
42 (39) 
56 (52) 
9 (8) 
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Title: Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label phase 2 
study [20, 21] 
Study identifier NCT01889186,EudraCT number 2012-004027-20, M13-982 
Analysis population 
(continuation) 
 
Rai stage at study entry 
Stage III 
Stage IV 
Other 
 
19 (18) 
32 (30) 
56 (52) 
Binet stage at study entry 
Stage A–B 
Stage C 
 
65 (61) 
42 (39) 
Previous treatments, n (%)4 
Median number of previous treatments (range) 
Bendamustine 
Bendamustine refractory 
Fludarabine 
Fludarabine refractory 
Bendamustine or fludarabine refractory 
Idelalisib 
Ibrutinib 
Other B-cell receptor inhibitors  
 
2 (1–4) 
54 (50) 
38 (70) 
78 (73) 
34 (44) 
62 (58) 
1 (1) 
3 (3) 
1 (1) 
Bulky disease 
One or more nodes ≥ 5 cm 
No nodes ≥ 5 cm 
 
57 (53) 
50 (47) 
TP53 mutation5 
Yes 
No 
Intermediate 
Missing 
 
60 (56) 
17 (16) 
6 (6) 
24 (22) 
IGHV mutation 
Yes 
No 
Missing 
 
7 (7) 
30 (28) 
70 (65) 
11q deletion 
Deleted  
Not deleted 
 
30 (28) 
77 (72) 
Absolute lymphocyte count 
≥ 25 x 109 cell per L 
< 25 x 109 cell per L 
Median (x109) 
 
54 (50) 
53 (50) 
25.8 (7.9–8.9) 
 Serum β-2 microglobulin 
< 3 mg/L 
≥ 3 mg/L 
Missing 
 
4 (4) 
13 (12) 
90 (84) 
Disease-related complications 
Neutropenia 
Anaemia 
Thrombocytopenia 
 
24 (22) 
22 (21) 
16 (15) 
Tumour lysis syndrome risk category 
Low 
Medium  
High 
 
19 (18) 
43 (40) 
45 (42) 
                                                             
4
 Refractory status was defined as no response or disease progression within 6 months of treatment  
5
 Investigator reported 
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Title: Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label phase 2 
study [20, 21] 
Study identifier NCT01889186,EudraCT number 2012-004027-20, M13-982 
Critical appraisal 
Study strengths 
 
 The study objective, patient characteristics, main outcomes, findings, 
and estimates of variability were clearly described. 
 Withdrawals and losses to follow-up were fully reported. 
 Appropriate statistical tests were used to evaluate results and the 
probability value was reported for the main outcome.  
 An independent review committee assessed ORR defined as partial re-
mission or higher. 
Study limitations 
 
 Insufficient follow-up to determine intended effects (DOR based on 13 
events), (PFS – 31 events), (OS – 17 deaths) and all potential serious 
AEs.  
 Per-protocol analysis, where a comparison of treatment includes only 
those patients who completed the treatment originally allocated, may 
lead to bias. Intention-to-treat analysis, a comparison of treatment 
groups that includes all patients as originally allocated, may be used to 
reduce the potential for bias.  
 Risk of overestimate of effect in using an open-label, single-arm, co-
hort study design with historical control to determine overall ORR as 
patients may have been recruited, selected, or assessed differently over 
time. A simultaneous control group would control for > 1 confounder; 
an RCT with adequate generation of randomisation, concealment of al-
location and blinded assessment would reduce the risk of overestimat-
ing the effect. 
 Study subjects may not be generalisable to the population or repre-
sentative of the population from whom they were derived. Patient se-
lection sampling was not fully reported, nor was the proportion of the 
population sampled.  
 The funders participated in the study design, conduct, analysis, inter-
pretation of data, writing, review and publication.  
Abbreviations: ALT = alanine aminotransferase, ANC = absolute neutrophil count, aPTT = activated partial thromboplastin time, 
AST = aspartate aminotransferase, CLL = chronic lymphocytic leukaemia, CTC = Common Toxicity Criteria, DOR = duration 
of response, IWCLL NCI-WG = International Workshop for Chronic Lymphocytic Leukaemia –National Cancer Institute-Working 
Group, ECOG = Eastern Cooperative Oncology Group, OS = overall survival, PFS: progression free survival, PT = prothrombin 
time 
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Table 4: Study quality assessment by Downs and Black [23]  
Assessment of study quality, modified Downs and Black checklist for randomised and non-randomised studies 
Reporting Yes/No/Partially Score 
1. Is the objective of the study clear? Yes=1, No=0  
2. Are the main outcomes clearly described in the Introduction or Methods? Yes=1, No=0  
3. Are characteristics of the patients included in the study clearly described? Yes=1, No=0  
4. Are the interventions clearly described? Yes=1, No=0  
5. Are the distributions of principal confounders in each group of subjects clearly described? Yes=2, Partially=1, No=0  
6. Are the main findings of the study clearly described? Yes=1, No=0  
7. Does the study estimate random variability in data for main outcomes? Yes=1, No=0  
8. Have all the important adverse events consequential to the intervention been reported? Yes=1, No=0  
9. Have characteristics of patients lost to follow-up been described? Yes=1, No=0  
10. Have actual probability values been reported for the main outcomes except probability 
< 0.001? 
Yes=1, No=0  
11. Is the source of funding clearly stated? Yes=1, No=0  
External validity Yes/No/Unclear Score 
12. Were subjects asked to participate in the study representative of the entire population 
recruited? Yes=1, No=0, Unclear=0  
13. Were those subjects who were prepared to participate representative of recruited the 
population? Yes=1, No=0, Unclear=0  
14. Were staff, places and facilities where patients were treated representative of the 
treatment most received? Yes=1, No=0, Unclear=0  
Internal validity Yes/No/Unclear Score 
15. Was an attempt made to blind study subjects to the intervention? 
Yes=1, No=0,  
Unclear=0  
16. Was an attempt made to blind those measuring the main outcomes? Yes=1, No=0,  
Unclear=0  
17. If any of the results of the study were based on data dredging, was this made clear? 
Yes=1, No=0,  
Unclear=0  
18. Was the time period between intervention and outcome the same for the intervention 
and control groups or adjusted for? 
Yes=1, No=0,  
Unclear=0  
19. Were statistical tests used to assess main outcomes appropriate? 
Yes=1, No=0,  
Unclear=0  
20. Was compliance with the interventions reliable? Yes=1, No=0,  
Unclear=0  
21. Were main outcome measures used accurate? (valid and reliable) 
Yes=1, No=0,  
Unclear=0  
Internal validity-cofounding (selection bias) Yes/No/Unclear Score 
22. Were patients in different intervention groups recruited from the same population? Yes=1, No=0,  
Unclear=0 
 
23. Were study subjects in different intervention groups recruited over the same period of 
time? 
Yes=1, No=0,  
Unclear=0  
24. Were study subjects randomised to intervention groups? 
Yes=1, No=0,  
Unclear=0  
25. Was the randomised intervention assignment concealed from patients and staff until re-
cruitment was complete? 
Yes=1, No=0,  
Unclear=0  
26. Was there adequate adjustment for confounding in the analyses from which main find-
ings were drawn? 
Yes=1, No=0,  
Unclear=0  
27. Were losses of patients to follow-up taken into account? Yes=1, No=0, Unclear=0  
Power 
Size of smallest interven-
tion group 
Score 0-5 
Score 
28. Was the study sufficiently powered to detect clinically important effects where the 
probability value for a difference due to chance is < 5%?   
 
